|Description||Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.|
|DrugBank||Primary Accession Number: DB01128|
|Type||Approved, Small Molecule|
|Indication||For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.|
|Mechanism of Action||Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.|
|Absorption||Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.|
You need to load/activate the cURL extension (http://www.php.net/cURL).